What You Should Know:
– Diagnostic Robotics has announced the closing of a $45M Series B funding round led by StageOne investors, with participation from Mayo Clinic, thus becoming a Mayo Clinic Platform portfolio company. Technion – Israel Institute of Technology, as well as other existing investors such as strategic angel investor Bradley Bloom, co-founder of Berkshire Partners, participated in this funding round as well.
– The new funding will be used to accelerate product development, go-to-market growth, including investment in sales and marketing, and other key hires across the organization.
AI-Driven Patient Care
Founded in 2017, Diagnostic Robotics leverages diagnostic system uses AI and predictive analytics models to solve a global challenge: strained health budgets and workforces. Diagnostic Robotics has helped notable customers such as Blue Cross & Blue Shield of Rhode Island, carry out care management programs and leverage AI to home in on predicting patient risk in a precise and impactful way to improve patient outcomes and care paths. Before co-founding Diagnostic Robotics in her current role as CEO, Dr. Kira Radinsky was eBay’s director of data science and chief scientist in Israel. Dr Radinsky is a visiting Professor at the Technion – Israel Institute of Technology and was previously a board member at HSBC as a leading expert in AI.
To date, Diagnostic Robotics has engineered predictive models focused on avoidable emergency room visits, prevention of congestive heart failures deterioration, and serious mental illness, among others. The company continues to engineer additional models and other platforms as part of its expanding product offering.
“Diagnostic Robotics is using the most precise predictive models, leveraging nuanced definitions of risk and shifting focus away from purely risk-based targeting to clinically-actionable targeting to not only change how health plans approach their members, but to drastically improve member clinical care journeys,” said Radinsky.
